This company listing is no longer active
DMKP.Q Stock Overview
A clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
DMK Pharmaceuticals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$1.04 |
| 52 Week Low | US$0.000001 |
| Beta | 1.35 |
| 11 Month Change | -99.00% |
| 3 Month Change | 0% |
| 1 Year Change | -100.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure
Sep 30Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.
Jul 29Adamis CEO urges stock split approval, slate of directors in letter to shareholders
Jul 21Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope
Apr 13Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic
Jan 20Adamis Pharmaceuticals: It's Now Or Never
Dec 02Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines
Sep 03Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares
Jun 13Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19
Jun 07Adamis pharmaceuticals gets deficiency letter from NASDAQ
May 28Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering
Jan 29Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose
Nov 16Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue
Nov 09Shareholder Returns
| DMKP.Q | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 2.2% |
| 1Y | -100.0% | 10.0% | 31.7% |
Return vs Industry: DMKP.Q underperformed the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: DMKP.Q underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| DMKP.Q volatility | |
|---|---|
| DMKP.Q Average Weekly Movement | 466,513.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DMKP.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: DMKP.Q's weekly volatility has increased from 198704% to 466513% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 12 | Eddie Glover | www.dmkpharmaceuticals.com |
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company’s lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
DMK Pharmaceuticals Corporation Fundamentals Summary
| DMKP.Q fundamental statistics | |
|---|---|
| Market cap | US$10.00 |
| Earnings (TTM) | -US$21.33m |
| Revenue (TTM) | US$3.62m |
0.0x
P/S Ratio0.0x
P/E RatioIs DMKP.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMKP.Q income statement (TTM) | |
|---|---|
| Revenue | US$3.62m |
| Cost of Revenue | US$4.97m |
| Gross Profit | -US$1.35m |
| Other Expenses | US$19.98m |
| Earnings | -US$21.33m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.11 |
| Gross Margin | -37.30% |
| Net Profit Margin | -589.28% |
| Debt/Equity Ratio | 0% |
How did DMKP.Q perform over the long term?
See historical performance and comparison